About this trial
This clinical trial is looking at how creatine monohydrate and resistance training can help keep muscle strength and slow down prostate cancer growth. The main goal is to see if this combination can improve energy, physical ability, and overall quality of life. Participants will join a 52-week program that includes exercise sessions twice a week through telehealth.
The trial's ID number is NCT06112990. It is a Phase 3 trial, which means it is looking at how well the treatments work and how safe they are. This study is not FDA-regulated for drugs or devices. About 200 participants are expected to join.
Who can join
Men aged 18 and older with metastatic prostate cancer who are currently receiving hormone treatment can join. They should not have had certain treatments recently and need to be willing to follow the exercise and supplement plan. The trial team will confirm who is eligible to participate.
Condition
Metastatic Prostate Cancer
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into one of two groups. One group will do resistance training and take creatine supplements. The other group will also do resistance training but will take a placebo, which is a harmless substance that looks like creatine. Both groups will do their workouts at home with guidance through telehealth.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
Huntsman Cancer Institute
Salt Lake City, Utah